Neutralizing anti-IFN-β antibodies: How much more evidence do we need to use them in practice?

Neurology

Volumn 65, Issue 1, 2005, Pages 6-8

  Giovannoni, Gavin ^a   Goodman, Andrew ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; BETA1A INTERFERON; INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT THROMBOPOIETIN;

ANTIBODY PRODUCTION; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; ERYTHROCYTE APLASIA; EXPANDED DISABILITY STATUS SCALE; HUMAN; META ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AUTOANTIBODIES; DISEASE PROGRESSION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 22044443325     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000172080.54415.f1     Document Type: Editorial

References (16)

1. Francis GS, Rice GPA, Alsop JC, et al. Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55.
2. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology 2005;65:40-47.
3. Soelberg Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39.
4. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-889.
5. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
6. PRISMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
8. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of 3âIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
9. Perini P, Calabrese M, Biasi G, Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004;251: 305-309.
10. Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 2003;61(9 Suppl 5): S13-S17.
11. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
12. Bellomi F, Scagnolari C, Tomassini V, et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003;215:3-8.
13. Gneiss C, Reindl M, Lutterotti A, et al. Interferon-beta: the neutralizing antibody (NAB) titer predicts reversion to NAB negativity. Mult Scler 2003; 9(Suppl 9):P482.S119.
14. Panitch H, Goodin DS, Francis G, et al. Evidence of interferon dose-response: European North American comparative efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-1506.
15. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-lb versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Independent Comparison of Interferon (INCOMIN) Trial Study Group. Lancet 2002;359:1453-1460.
16. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care 1999;2:1-6.